Quoin Pharmaceuticals Ltd DRC (QNRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Quoin Pharmaceuticals Ltd DRC (QNRX) has a cash flow conversion efficiency ratio of -0.555x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.87 Million) by net assets ($8.77 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See QNRX defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Quoin Pharmaceuticals Ltd DRC - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Quoin Pharmaceuticals Ltd DRC's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Quoin Pharmaceuticals Ltd DRC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Quoin Pharmaceuticals Ltd DRC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Metal Bank Ltd
AU:MBK
|
-0.024x |
|
Encorp Bhd
KLSE:6076
|
0.379x |
|
Nyrstar NV
BR:NYR
|
0.000x |
|
Jungo Connectivity Ltd
TA:JNGO
|
N/A |
|
Jupiter Neurosciences, Inc. Common Stock
NASDAQ:JUNS
|
1.293x |
|
Courtois S.A
PA:COUR
|
-0.010x |
|
Dundas Minerals Ltd
AU:DUN
|
-0.089x |
|
Major Development Public Company Limited
BK:MJD
|
-0.052x |
Annual Cash Flow Conversion Efficiency for Quoin Pharmaceuticals Ltd DRC (2015–2025)
The table below shows the annual cash flow conversion efficiency of Quoin Pharmaceuticals Ltd DRC from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see Quoin Pharmaceuticals Ltd DRC stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $13.12 Million | $-13.54 Billion | -1032.095x | -120807.81% |
| 2024-12-31 | $9.20 Million | $-7.86 Million | -0.854x | +38.52% |
| 2023-12-31 | $5.66 Million | $-7.86 Million | -1.388x | -21.27% |
| 2022-12-31 | $7.41 Million | $-8.48 Million | -1.145x | +86.85% |
| 2021-12-31 | $657.03K | $-5.72 Million | -8.706x | -4397.13% |
| 2020-12-31 | $-6.61 Million | $-1.34 Million | 0.203x | +115.25% |
| 2019-12-31 | $4.30 Million | $-5.71 Million | -1.329x | +24.69% |
| 2018-12-31 | $3.73 Million | $-6.57 Million | -1.764x | -92.44% |
| 2017-12-31 | $5.43 Million | $-4.98 Million | -0.917x | -80.15% |
| 2016-12-31 | $7.40 Million | $-3.77 Million | -0.509x | +30.78% |
| 2015-12-31 | $2.70 Million | $-1.98 Million | -0.735x | -- |
About Quoin Pharmaceuticals Ltd DRC
Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrom… Read more